The latest polls from Channels 11, 12 and 13, were conducted after the lists for the March 2 elections were submitted.
The Alaskan Native Corporations are an example of how we should gas revenues to give all Israelis a greater share in their country's wealth.
The revised Israel-UK Protocol now in force has been warmly welcomed.
Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.
Ashdod plans 15 hotels with 4,000 rooms built in the coming decade for its seafront with cheaper prices for tourists than Tel Aviv.
What will happen to work when reality is no longer real, asks Nirit Cohen.
Michael Li, founder and president of The Data Incubator, talks about the need for more data scientists worlwide and in Israel.
It isn't Hamas rockets - the answer lies closer to home.
The poverty report is about inequality, not children without food. The report's authors and media ignore this and make demagogic statements, says Dr. Michael Sarel.
A new Swiss initiative will enable startups from the two countries to learn from each other's strengths.
eToro's main platform continues to be a social investments network in which every investor can see in which assets other investors are investing.
The gas from Leviathan came ashore on time, exports look set, but Israeli factories still await hook-up, and no-one even knows who should decide on conflicts with Tamar.
Israel may be a world vehicle technology power, but driverless cars face many regulatory obstacles before they'll be allowed on the country's roads.
Transport & infrastructure
After the biggest ever Israeli cybersecurity company exit, the founders say they remain independent and retain their vision of an IPO and building a huge IoT security company.
Mergers & acquisitions
"Globes" traces how Israel's Greidinger family has built the world's biggest cinema chain despite the challenge posed by Netflix.
Telecoms, Media & Marketing
VP discovery David Wilson tells "Globes" that Teva is still an innovative company and has turned its attention back to Israel in the search for new drug candidates.
The answer is yes, as long as it knows how to implement the low-cost model.
Co-founder Hillel Kobrinsky: We looked for a business problem, and then developed the technology, not the other way around.